HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
July 21, 2003
- Teijin Enters into License Agreement with Ipsen
July 21, 2003
- MEDICAL DEVICE NEWS IN BRIEF
July 21, 2003
- Fukujin Aims to Be No. 1 Wholesaler 3 Years After Merger
July 21, 2003
- Kringle Pharma Hopes for Global Expansion via Alliances
July 21, 2003
- BUSINESS NEWS IN BRIEF
July 21, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
July 21, 2003
- NEW PRODUCTS NEWS IN BRIEF
July 21, 2003
- Pfizer to Contain Share of Diflucan Generics to 5-10%
July 21, 2003
- Chuikyo Subcommittee Discusses Environment to Promote GE Use
July 21, 2003
- WORLD NEWS IN BRIEF
July 21, 2003
- Gov't to Study Stronger Protection of New Drug Data
July 21, 2003
- Developing New Non-viral
July 21, 2003
- Precautions for 10 Drugs to Be Revised
July 21, 2003
- GSK to Revise Promotion Strategy for Imigran
July 21, 2003
- REGULATORY NEWS IN BRIEF
July 21, 2003
- Meiji Seika's GE Business Showing Steady Progress
July 21, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 21, 2003
- Taisho Drops 7 of 11 Compounds from Bioventures
July 14, 2003
- CTD Applications Become Obligatory on July 1
July 14, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
